Scorr-Insert
X

Find Novel Neurology Drugs in Preclinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aav Vectors

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Facial Pain Research Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 20, 2020

            Details:

            Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Stem cell therapy

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Polaris Partners

            Deal Size: $42.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing May 13, 2020

            Details:

            QurAlis intends to use this funding to support the development of new therapies for ALS and genetically related frontotemporal dementia (FTD), neurodegenerative diseases for which there is currently no cure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): siRNAs

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Alzheimer's Association

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Funding May 13, 2020

            Details:

            The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Progranulin

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            Details:

            Alpha Cognition has been granted 2 EU patents relating to the use of progranulin to treat neurodegenerative diseases. Progranulin, alpha-602, is a protein, capable of protecting stressed neurons.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trehalose API

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            The allowed claims cover the composition of matter and method of use for trehalose (SLS-005) for treating diseases or disorders which include Spinal and bulbar muscular atrophy (SBMA) and other.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VB-601

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            VBL Therapeutics's anti-MOSPD2 antibodies that block monocyte migration without affecting T-cells, were able to recapitulate this effect and profoundly reduced inflammation and tissue damage.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PR001

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2020

            Details:

            Preclinical data demonstrate potential of Prevail’s AAV gene therapy approach to slow or halt progression in multiple neurodegenerative diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Funapide

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NB-02

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 21, 2020

            Details:

            The patent covers the extract of a mixture containing mulberry and Poria cocos peel, active ingredients contained in the composition, for treating a degenerative neurological disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SBT-272

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Morningside Venture

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 13, 2020

            Details:

            The Company expects to use proceeds from this capital raise to advance the Company's ongoing development of its lead candidate, elamipretide, its next-generation clinical stage compound, SBT-272.

            PharmaCompass